- Home
- STTK vs ISTR Comparison
STTK vs ISTR Comparison
Compare STTK & ISTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ISTR
- Stock Information
- Founded
- STTK 2016
- ISTR 2006
- Country
- STTK United States
- ISTR United States
- Employees
- STTK N/A
- ISTR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ISTR Major Banks
- Sector
- STTK Health Care
- ISTR Finance
- Exchange
- STTK Nasdaq
- ISTR Nasdaq
- Market Cap
- STTK 37.6M
- ISTR 189.6M
- IPO Year
- STTK 2020
- ISTR 2014
- Fundamental
- Price
- STTK $0.83
- ISTR $21.87
- Analyst Decision
- STTK Hold
- ISTR Buy
- Analyst Count
- STTK 4
- ISTR 1
- Target Price
- STTK $3.00
- ISTR $27.00
- AVG Volume (30 Days)
- STTK 480.9K
- ISTR 46.5K
- Earning Date
- STTK 07-31-2025
- ISTR 07-21-2025
- Dividend Yield
- STTK N/A
- ISTR 1.89%
- EPS Growth
- STTK N/A
- ISTR 22.25
- EPS
- STTK N/A
- ISTR 2.19
- Revenue
- STTK $4,606,000.00
- ISTR $88,885,000.00
- Revenue This Year
- STTK N/A
- ISTR $2.04
- Revenue Next Year
- STTK N/A
- ISTR $9.79
- P/E Ratio
- STTK N/A
- ISTR $10.04
- Revenue Growth
- STTK 69.65
- ISTR 6.35
- 52 Week Low
- STTK $0.69
- ISTR $15.39
- 52 Week High
- STTK $4.99
- ISTR $24.81
- Technical
- Relative Strength Index (RSI)
- STTK 38.86
- ISTR 70.31
- Support Level
- STTK $0.75
- ISTR $21.97
- Resistance Level
- STTK $0.85
- ISTR $22.46
- Average True Range (ATR)
- STTK 0.09
- ISTR 0.68
- MACD
- STTK -0.01
- ISTR 0.32
- Stochastic Oscillator
- STTK 9.59
- ISTR 90.89
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ISTR Investar Holding Corporation
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashiers' checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.